Art. 116 Directive (EU) 2001/83

In forcesince 21 Jul 2011cited 30×

The competent authorities shall suspend, revoke or vary a marketing authorisation if the view is taken that the medicinal product is harmful or that it lacks therapeutic efficacy, or that the risk-benefit balance is not favourable, or that its qualitative and quantitative composition is not as declared. Therapeutic efficacy shall be considered to be lacking when it is concluded that therapeutic results cannot be obtained from the medicinal product.

A marketing authorisation may also be suspended, revoked or varied where the particulars supporting the application as provided for in Articles 8, 10, 10a, 10b, 10c or 11 are incorrect or have not been amended in accordance with Article 23, or where any conditions referred to in Articles 21a, 22 or 22a have not been fulfilled or where the controls referred to in Article 112 have not been carried out.

The second paragraph of this Article also applies in cases where the manufacture of the medicinal product is not carried out in compliance with the particulars provided pursuant to point (d) of Article 8(3), or where controls are not carried out in compliance with the control methods described pursuant to point (h) of Article 8(3).

The 10 that are cited most themselves, of 30.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…14bLaw

    … angiver navnlig, om en sådan foranstaltning er baseret på nogen af de grunde, der er nævnt i artikel 116 eller artikel 117, stk. 1, i direktiv 2001/83/EF. 2. Indehaveren af markedsføringstilladelsen foretager ligeledes underretning i …

  • Directive (EU) 2004/27Lawamends

  • Judgment of the Court of First Instance (Second Chamber, extended composition) of 26 November 2002. Artegodan GmbH and Others v Commission oDecision

    Against that background, contrary to the applicants' arguments, the proposal submitted by the Commission on 26 November 2001 for a directive amending Directive 2001/83/EC on the Code (COM (2001) 404 final), which seeks specific reference …

    26 Nov 2002 · 62000TJ0074

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    URTEIL DES GERICHTS (Fünfte Kammer) 11. Dezember 2014( * ) „Humanarzneimittel – Wirkstoff Tolperison – Art. 116 der Richtlinie 2001/83/EG – Beschluss der Kommission, mit dem gegenüber den Mitgliedstaaten die Änderung der …

    11 Dec 2014 · 62013TJ0189

  • Judgment of the Court (Sixth Chamber), 10 April 2014. Acino AG v European Commission.Decision

    Article 116 of Directive 2001/83 provides as follows: ‘The competent authorities shall suspend, revoke, withdraw or vary a marketing authorisation if the view is taken that the product is harmful under normal conditions of use, or that …

    10 Apr 2014 · 62013CJ0269

  • Arrêt de la Cour (huitième chambre) du 3 décembre 2015. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    À l’appui de son pourvoi, Nature-Balance soulève, en substance, trois moyens. Les deux premiers moyens sont respectivement pris d’une violation des articles 116 et 10 bis de la directive 2001/83. Le troisième moyen est tiré d’une …

    3 Dec 2015 · 62015CJ0082

  • Directive (EU) 2010/84Lawamends

  • Arrêt du Tribunal (septième chambre) du 7 mars 2013. Acino AG (anciennement Acino Pharma GmbH) contre Commission européenne.Decision

    … eigene Erwägungen der Kommission nennt, aus denen erkennbar ist, dass diese ihr Ermessen ausgeübt hat, um in den Art. 116 und 117 der Richtlinie 2001/83 vorgesehene Maßnahmen zu erlassen. In der Tat hat die Kommission im zweiten …

    7 Mar 2013 · 62010TJ0539

  • Judgment of the General Court (Fourth Chamber) of 19 September 2019. GE Healthcare A/S v European Commission.Decision

    In support of its action, the applicant relies on five pleas in law alleging, first, infringement of Article 116 of Directive 2001/83, second, infringement of the precautionary principle, third, infringement of the principle of equal …

    19 Sep 2019 · 62017TJ0783

  • Directive (EU) 2011/62Lawamends